Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
placebo + tecemotide
- Development stage
- Unknown
- Lead developer
- Merck KGaA
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
This is a combination of placebo and tecemotide, used as a control or comparator arm in clinical trials evaluating the efficacy and safety of tecemotide. Tecemotide is a synthetic lipopeptide antigen used in investigational therapeutic cancer vaccines designed to induce an immune response against MUC1, a glycoprotein antigen overexpressed on various cancers such as lung, breast, prostate, and colorectal cancer. The vaccine aims to stimulate cellular immunity leading to tumor rejection. Placebo serves as an inactive substance for comparison purposes in clinical studies[2][3][8].
02
Targets
MUC1 (Mucin-1 Antigen)
Beyond the preview
Go deeper on placebo + tecemotide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on placebo + tecemotide.